tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Dianthus initiated with an Outperform at William Blair

William Blair initiated coverage of Dianthus (DNTH) with an Outperform rating. Dianthus is a clinical-stage biotech company developing DNTH103 for autoimmune neuromuscular indications, notes the analyst, who sees fair value of $47.57 per share.

Elevate Your Investing Strategy:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1